STAT+: HHS moves to allow compounding of some unapproved peptides

RFK Jr. has embraced peptides, though there’s little evidence of their safety or effectiveness Adobe Margaret is a Washington correspondent covering the Food and Drug Administration and other federal health agencies. Reach her on Signal at margaretmanto.61. WASHINGTON — The Department of Health and Human Services released a policy that will temporarily allow compounding pharmacies to manufacture some peptide products, increasing access to the experimental wellness therapies embraced by many in the Make America Healthy Again movement. The policy states that HHS will use “enforcement discretion” to not take action against state-licensed pharmacies, federal facilities, or licensed physicians compounding the six peptides previously backed by a Food and Drug Administration advisory committee. The proposal comes as the FDA continues to weigh whether to allow compounding pharmacies to manufacture peptides. In July, an FDA advisory panel voted to recommend that these pharmacies be cleared to manufacture six of these substances. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Margaret is a Washington correspondent covering the Food and Drug Administration and other federal health agencies. Reach her on Signal at margaretmanto.61.